
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant is performing well in terms of financials with a reported loss per share of $0.73 in 4Q26, slightly higher than the estimated and street consensus. With strong data and validation of their anti-FcRn mechanism, a potential FDA approval for IMVT-1402 would likely drive revenue of $749M, providing good potential for growth in the next few years. However, there are risks involved, mainly regarding regulatory and clinical approval, the impact of COVID-19 on clinical development, and the competitive market for their first product launch. Overall, the financials and potential market opportunity for Immunovant make it a promising stock for investors with a higher risk tolerance.
Bears say
Immunovant is positioned to address autoimmune diseases with their lead candidate IMVT-1402, an FcRn inhibitor. Their ongoing Phase 2 study has shown high efficacy in Period 1, and the company has enough cash to support operations through the potential launch of IMVT-1402 in generalized dermatomyositis, making them an attractive prospect. However, the statis
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares